Sponsor or institution

Clinical trials and research at Genmab

• 14Clinical trials
• 25Countries

Newest trials

All recruiting trials (14)

• Petosemtamab plus chemotherapy vs standard chemo plus cetuximab or bevacizumab in RAS/BRAF WT colorectal cancer

  This phase 3 trial tests whether adding petosemtamab to standard chemotherapy works better than the usual chemo plus cetuximab or bevacizumab for people with recurrent, unresectable, or metastatic colorectal cancer that is KRAS/NRAS/BRAF wild type.

  Recruiting at 5 sites Phase 3 Genmab · Hot Springs, Arkansas and 4 other locations · NCT07775287

• Petosemtamab plus chemotherapy vs cetuximab plus chemotherapy in left-sided unresectable or metastatic colorectal cancer

  This trial tests whether adding petosemtamab to standard chemotherapy works better than cetuximab with chemotherapy for adults with left-sided, unresectable or metastatic colorectal cancer that is KRAS/NRAS wild-type.

  Recruiting at 12 sites Phase 3 Genmab · Hot Springs, Arkansas and 11 other locations · NCT07702032

• GEN1119 in people with solid tumors

  This phase 1 trial tests GEN1119 in adults with solid cancers to see if it is safe and how it behaves in the body and may show signs of activity against tumors.

  Recruiting at 8 sites Phase 1 Genmab · Rennes, Ille Et Vilaine and 7 other locations · NCT07695831

• Rina-S extension study in platinum-resistant ovarian cancer in China

  This study tests whether Rina-S works as well as standard chemotherapy options for people with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer in China.

  Recruiting at 17 sites Phase 3 Genmab · Changchun and 16 other locations · NCT07604766

• Rina-S with or without bevacizumab after platinum therapy for recurrent platinum-sensitive ovarian cancer

  This trial tests whether Rina-S alone or with bevacizumab works better than the investigator’s choice platinum-based chemotherapy (with or without bevacizumab) for patients with recurrent platinum-sensitive ovarian cancer.

  Recruiting at 12 sites Phase 3 Genmab · Duarte, California and 11 other locations · NCT07564141

• Rina-S for advanced gastrointestinal cancers

  This Phase 2 trial will try Rina-S alone in people with metastatic or unresectable gastrointestinal cancers that have progressed after standard treatments to see if it can control the disease.

  Recruiting at 28 sites Phase 2 Genmab · Los Angeles, California and 27 other locations · NCT07539311

• GEN1106 for solid tumors, including metastatic urothelial (bladder) cancer.

  This trial tests a new drug called GEN1106 in people with metastatic solid tumors, especially urothelial (bladder) cancer, who have progressed after standard treatments.

  Recruiting at 9 sites Phase 1 Genmab · New Haven, Connecticut and 9 other locations · NCT07416123

• GEN1079 treatment for advanced solid tumors

  This trial will test whether the antibody GEN1079 is safe and can help people with advanced solid tumors.

  Recruiting at 12 sites Phase 1 Genmab · New Haven, Connecticut and 11 other locations · NCT07387068

• GEN3018 for relapsed or treatment‑resistant acute myeloid leukemia and higher‑risk MDS

  This trial will test a new antibody drug called GEN3018 in adults whose AML or higher‑risk MDS has relapsed or not responded to prior treatments.

  Recruiting at 6 sites Phase 1 Genmab · Aarhus, Denmark and 8 other locations · NCT07384715

• Rina-S treatment for advanced non-small cell lung cancer

  This Phase 2 trial will test whether Rina-S by itself can shrink or control advanced non-small cell lung cancer in people whose cancer has progressed after prior treatment.

  Recruiting at 102 sites Phase 2 Genmab · Fountain Valley, California and 101 other locations · NCT07288177

• Rina-S plus standard care versus standard care as maintenance after second-line platinum chemotherapy for recurrent platinum-sensitive ovarian cancer

  This trial will test whether adding Rina-S to standard maintenance care helps people with recurrent platinum-sensitive ovarian cancer stay cancer-free longer after second-line platinum chemotherapy.

  Recruiting at 34 sites Phase 3 Genmab · Miami, Florida and 33 other locations · NCT07225270

• Rina-S versus standard chemotherapy for recurrent or progressive endometrial cancer

  This trial tests whether Rina-S (GEN1184) works better than the doctor's choice of chemotherapy (paclitaxel or doxorubicin) for people with recurrent or progressive endometrial cancer who have had prior platinum-based chemotherapy and a PD-(L)1 inhibitor.

  Recruiting at 178 sites Phase 3 Genmab · Mobile, Alabama and 177 other locations · NCT07166094

• Testing Rinatabart Sesutecan for advanced solid tumors

  This study is testing a new drug called Rinatabart Sesutecan to see if it can safely help people with advanced solid tumors, like certain types of ovarian and endometrial cancers.

  Recruiting at 67 sites Phase 1/2 Genmab · Phoenix, Arizona and 66 other locations · NCT05579366

• Testing a new bispecific antibody for advanced solid tumors

  This study is testing a new treatment called MCLA-158 to see if it can help people with advanced solid tumors, especially those with metastatic colorectal cancer, when other options have run out.

  Recruiting at 45 sites Phase 1/2 Genmab · La Jolla, California and 53 other locations · NCT03526835

Quick answers

How many clinical trials run by Genmab are recruiting right now?

14, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 25 countries. The most sites are in United States (11 trials), Spain (9 trials), Japan (8 trials), France (6 trials), Belgium (5 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 6, Phase 1: 4, Phase 1/2: 2, Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →